Rewalk Robotics Ltd (NASDAQ:RWLK) has received a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $3.10.
A number of equities analysts recently issued reports on the company. Jefferies Group lowered their price target on Rewalk Robotics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Oppenheimer set a $3.00 price objective on Rewalk Robotics and gave the company a “buy” rating in a report on Tuesday, December 26th. Zacks Investment Research raised Rewalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Thursday, November 9th. Canaccord Genuity reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Rewalk Robotics in a report on Monday, November 6th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Rewalk Robotics in a report on Sunday.
A hedge fund recently raised its stake in Rewalk Robotics stock. Advisor Group Inc. increased its stake in shares of Rewalk Robotics Ltd (NASDAQ:RWLK) by 1,495.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 181,900 shares of the medical device company’s stock after purchasing an additional 170,500 shares during the period. Advisor Group Inc. owned 0.82% of Rewalk Robotics worth $264,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 3.23% of the company’s stock.
Rewalk Robotics (NASDAQ:RWLK) last released its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.10. Rewalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.63 million. During the same quarter last year, the company posted ($0.62) earnings per share. The business’s revenue was up 21.4% on a year-over-year basis. equities research analysts forecast that Rewalk Robotics will post -1.14 earnings per share for the current fiscal year.
Rewalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.